

December 21, 2021

## **VIA EDGAR**

United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549

RE: Forward Pharma A/S

Registration Statement on Form F-3

Filed December 13, 2021 File No. 333-261626

## Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Forward Pharma A/S (the "<u>Registrant</u>") hereby requests that the effectiveness of the Registration Statement on Form F-3 (File No. 333-261626) (the "<u>Registration Statement</u>") be accelerated so that the Registration Statement becomes effective at 4:00 p.m. (New York City time) on December 23, 2021 or as soon thereafter as is practicable.

Please contact Ryan A. Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8373 if you have any questions concerning the foregoing. Thank you for your attention to this matter.

\* \* \*

Very truly yours,

## FORWARD PHARMA A/S

By: /s/ Claus Bo Svendsen
Name: Claus Bo Svendsen, MD, PhD Title: Chief Executive Officer

Ryan A. Murr, Gibson, Dunn & Crutcher LLP

cc: